IRD
Opus GeneticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful clinical/data milestones or a strategic partnership/licensing deal could materially re-rate the stock, validating platform potential and improving near-term financing prospects.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Clinical trial failure or negative data readout
Momentum
9
Value
41
Sentiment
7
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.82 · Bull $2.91 · Bear $0.91
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.65
Why
Momentum9 · Δ7d -4.9
Value41 · Δ7d +0.0
Sentiment7 · Δ7d +3.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
9
26% active weight
Current posture
7d trendFlat
Δ7d
-4.9
Δ21d
-13.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
7
34% active weight
Current posture
7d trendImproving
Δ7d
+3.5
Δ21d
+3.5
Why this grade
Composite grade F. Momentum 8.8 / Value 41.1 / Sentiment 7.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$251.83M
Beta
0.58
Shares Out
82.57M
P/E (TTM) · Derived
-3.8
P/S (TTM)
10.04
P/FCF (TTM) · Derived
-5.69
Rev YoY
-50.6%
EPS YoY
+211.9%
Gross Margin
+99.6%
Op Margin
-445.4%
Net Debt
-$43.96M
Current Ratio
7.13
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology